



Documentation of the Evidence leading to the final SSI Guideline and declaration of author's conflict of interest

1. Selection process for Swiss or International Guidelines

1.1. What guidelines were considered for the selection

Year of publication	Name of Organization	Link to pdf or PMID	Swiss / Intl
2018	BASHH National guideline for the management of infections with Mycoplasma genitalium	https://www.bashhguidelines.org/current-guidelines	Intl.
2018	Australian STI Management Guidelines for Use in Primary Care.	http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium#clinical-presentation	Intl.
2021	CDC Sexually Transmitted Infections Treatment Guidelines 2021. Mycoplasma genitalium	https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm	Intl.

Comment: *(e.g. if no reference guideline could be found)*

1.2. Final selection of the reference Guideline

The following guideline was considered as the reference* guideline for the SSI:

Name of Organization / Guideline / PMID:

- British Association for Sexual Health and HIV (BASHH) / National guideline for the management of infections with Mycoplasma genitalium.

Date of decision: 05 / 2020

**In special settings, an additional guideline (e.g. pediatric) can be added as a reference guideline:*

Guideline:

Remarks (e.g. short comment on the rationale for the decision)

2. Description of specific issues for Swiss guidelines

Please indicate which part of the guideline needs to be amended for the use in Switzerland. Enlarge table as needed. Try to *limit description of amendments to one page*.

Topic	Describe the change for the Swiss Guideline	Rationale for the change
Diagnostics	Recommendation: Screening for common STIs such as gonococci, Chlamydia trachomatis before screen for M. genitalium	
Diagnostics Resistance testing	Clearer recommendation to carry out resistance testing / not only when therapy fails	Macrolide resistance situation in Switzerland
Test of cure	Test of cure in asymptomatic patients not recommended in general Clinical follow-up	
Complications in men/women	Supplement: associations described	Data to weak
Treatment	Pristinamycin is mentioned as only 3 rd line treatment	Due to clinical experience

Date of final agreement within the expert group for these changes: 09/2021

Date	Author	Name of Guideline doc
11.10.21		SOP_M_genitalium_SSI_guidelines.BHdocx.docx

3. Declaration of author's conflict of interest

The authors declare the following conflicts of interest:

Ben Hampel:

- Received money from MSD, Gilead and Viiv for the institution
- Is member of the Federal Commission for Issues relating to Sexually Transmitted Infections (CFIST)

Julia Notter: no conflict of interest

Date	Author	Name of Guideline doc
11.10.21		SOP_M_genitalium_SSI_guidelines.BHdocx.docx